Online inquiry

IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12465MR)

This product GTTS-WQ12465MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL2RB gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000878.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3560
UniProt ID P14784
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ12465MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4816MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BT-061
GTTS-WQ5204MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CAT-8015
GTTS-WQ10990MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ8415MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HSP90mab
GTTS-WQ12796MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ14658MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ1967MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AGS-15E
GTTS-WQ3016MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Anti-Beta7
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW